Navigation Links
More Patients Receive Diovan As A First- Or Second-Line Therapy Compared With Cozaar or Avapro
Date:5/11/2009

New Treatment Algorithms Data from Decision Resources Allows Pharmaceutical Brand Managers to Build Patient-Flow Models that Better Forecast Market Share

WALTHAM, Mass., May 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that use of Novartis' Diovan in earlier lines of therapy compared with Merck's Cozaar is influenced by physician perception that the former is more effective and affordable for patients. Thirty-nine percent of surveyed cardiologists and 45 percent of surveyed PCPs consider Diovan superior to Cozaar in reducing systolic blood pressure. Twenty-nine percent of surveyed cardiologists and 38 percent of surveyed PCPs point to Diovan's lower cost--compared with Cozaar--as a reason to choose the agent. However, a sizeable group of surveyed physicians (30 percent of surveyed cardiologists and 28 percent of surveyed PCPs) view both agents as equivalent.

"Physicians have multiple generic options to choose from in first- and second-line treatment, including diuretics, angiotensin-converting enzyme inhibitors, calcium channel blockers and beta blockers. Nonetheless, we find that approximately half (51.7 percent) of the patients who were prescribed Diovan take the drug as a first- or second-line treatment, which allots a higher percentage of this agent's use to early lines of therapy compared with either Bristol-Myers Squibb/Sanofi-Aventis' Avapro or Cozaar. Surveyed physicians' responses suggest that Novartis' investment in clinical trials and formulary negotiations has helped Diovan gain some ground in the competitive AIIRA space," said Madhuri Borde, Ph.D., analyst at Decision Resources.

The new report entitled Treatment Algorithms in Hypertension also finds that 24.2 percent of patients starting Novartis' Exforge, which combines Diovan with amlodipine in a fixed-dose combination, previously received Diovan or the Diovan/diuretic fixed-dose combination Diovan HCT. A further 18.5 percent of patients moving to Exforge had been prescribed a calcium channel inhibitor in the previous line, indicating that fixed-dose combinations are keenly dependent on the penetration of their single-agent components as an access point.

"The unique data in the Treatment Algorithms in Hypertension report allows brand managers to accurately quantify the percentage of patients moving from first line to second line, the length of time patients are on a therapy before switching and the number of patients dropping therapy versus adding on," said Dr. Borde. "Each of these metrics is critical to building an accurate model of how patients move between therapies and is key in better estimating the potential pool of consumers."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS Lifelink: Health Plans Claims database to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Comparison of obstetric outcomes between on-call and patients own obstetricians
3. Vision restoration therapy shown to improve brain activity in brain injured patients
4. Diabetes appears to increase risk of death for patients with acute coronary syndromes
5. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
6. Restricting Blood Flow May Help Heart Bypass Patients
7. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
8. Study provides hope that some transplant patients could live free of antirejection drugs
9. Study provides hope that some transplant patients could live free of anti-rejection drugs
10. Longer ambulance journeys boost death risk for seriously ill patients
11. Expenses Overshadow Optimism for Kidney Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... the Affordable Care Act. Dr. Botelho advocates for the mass media launching of ... gives people ongoing opportunities to share their unfortunate experiences; such a movement can ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... serve communities in and around the greater Phoenix metropolitan region, is announcing a ... , The mission of the Homeless Youth Connection is to promote community awareness ...
(Date:12/7/2016)... ... 2016 , ... DrugDev again demonstrated its dedication to reducing the ... early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of Commerce. ... of the Atlantic with a mechanism to comply with EU data protection requirements when ...
(Date:12/7/2016)... ... December 07, 2016 , ... Silhouette Instalift is a ... smoothing and tightening the skin of the face to create more youthful features. ... with very little downtime, Silhouette Instalift is a novel, minimally invasive facial procedure ...
(Date:12/7/2016)... Linda, Ca (PRWEB) , ... December 07, 2016 , ... ... attain that funding is with useful, properly analyzed data. The team at Beckman Coulter ... to address the 'need for speed' and the need to operate in a GLP ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... True Health Diagnostics today announced a ... and management expertise to hospital systems throughout ... doctors and patients to benefit from state-of-the-art biomarker ... Logo - http://photos.prnewswire.com/prnh/20161208/447162LOGO ... to contain costs, have struggled to keep up ...
(Date:12/8/2016)... Information products and services provider Elsevier ... Scopus , the world,s largest abstract and citation database of peer-reviewed ... journals from over 5,000 publishers. The new set of metrics will ... and when to adjust a journal,s editorial strategy. ... , , ...
(Date:12/8/2016)... 8, 2016 A Small Business Innovative Research ... of Health (NIH) to Phoenix -based ... The grant will seek to determine an optimal ... utilizes electromagnetic waves to treat Alzheimer,s Disease. The grant ... to possibly treat other neurologic disorders such as Parkinson,s ...
Breaking Medicine Technology: